Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra, Inc. (NYSE American: AZTR) is a clinical stage biopharmaceutical company developing therapies for precision dermatology, and its news flow reflects the progress and challenges of an emerging biotechnology issuer. Company announcements frequently highlight updates on its lead program, ATR-12, which uses an engineered strain of Staphylococcus epidermidis to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. News items also cover milestones for ATR-04, an engineered S. epidermidis program for EGFR inhibitor (EGFRi)–associated rash and skin toxicity, and ATR-01, a preclinical program designed to treat ichthyosis vulgaris through filaggrin secretion.
Investors following AZTR news can expect regular coverage of clinical trial milestones, such as initiation of Phase 1b and Phase 1/2 studies, first-patient-dosed events, and the presentation of preclinical and clinical data at scientific and investor conferences. The company’s releases describe participation in events like BIO-Europe, Biotech Showcase, and investment conferences, where management discusses safety data, pharmacology results, and development strategy for ATR-12, ATR-04, and ATR-01.
News about Azitra also includes regulatory and listing developments, including notices from NYSE American regarding compliance with continued listing standards and acceptance of the company’s plan to regain compliance by a specified deadline. Additional articles cover capital markets activity, such as private placements, equity line of credit transactions, and related registration statements and proxy proposals tied to share issuances and warrants.
By monitoring this AZTR news page, readers can track how Azitra advances its live biotherapeutic and engineered protein programs in dermatology, how it responds to stock exchange compliance requirements, and how it structures financings to support ongoing clinical and preclinical work.
Azitra (NYSE American: AZTR) has received FDA clearance for an IND application to conduct a Phase 1/2 clinical study of ATR-04, targeting moderate to severe EGFR inhibitor-associated dermal toxicity. This condition affects an estimated 150,000 patients in the US, representing a global market size exceeding $1 billion. ATR-04, a live biotherapeutic product, has shown promise in preclinical studies by reducing IL-36γ and Staphylococcus aureus, key factors in EGFRi-associated skin rash. The company plans to initiate a multicenter, randomized, controlled trial by the end of 2024. This development expands Azitra's clinical pipeline, addressing a significant unmet need for cancer patients receiving EGFR inhibitors who often experience severe skin side effects.
Azitra (NYSE American: AZTR) has screened the first patient for its Phase 1b clinical trial of ATR-12, a potential treatment for Netherton syndrome. The trial aims to enroll 12 adult patients for a 14-day treatment period. Interim safety data is expected in early 2025, with full results anticipated in the second half of 2025.
ATR-12 is a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of an active LEKTI protein subunit. The trial's primary endpoints focus on safety and tolerability, while secondary endpoints assess efficacy signals and biomarkers. Recent preclinical data showed ATR-12's potential to reduce IL-36γ by 93% and significantly decrease protease activity in skin samples.
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Completed a $10 million follow-on offering, extending cash runway into 2025.
2. Strengthened global IP portfolio with new patents.
3. Presented positive preclinical data for ATR-04 and ATR-12.
4. Opened Phase 1b trial for ATR-12 in Netherton Syndrome.
5. Anticipates dosing first Netherton syndrome patient with ATR-12 in Q3 2024.
6. Expects to file and clear IND for ATR-04 in Q3 2024.
7. Plans to report initial ATR-12 Phase 1b safety data by year-end 2024.
8. Aims to dose first patient with ATR-04 for EGFRi rash by year-end 2024.
9. Expects topline data from ATR-12 Phase 1b trial in mid-2025.
Financial results: Q2 2024 service revenue $7,500, R&D expenses $1.1M, G&A expenses $1.5M, net loss $2.6M. Cash and equivalents as of June 30, 2024: $0.8M.
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has successfully closed its public offering of 16,667,000 shares of common stock at $0.30 per share. The offering raised approximately $5 million in gross proceeds. ThinkEquity acted as the sole book-running manager for the offering. Azitra plans to use the net proceeds for clinical trials, product development, research and development, clinical manufacturing, working capital, and other general corporate purposes. The company has also granted underwriters a 45-day option to purchase up to an additional 2,500,000 shares to cover over-allotments.
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has successfully closed its $10.0 million public offering. The offering included 6,665,000 shares of common stock and Class A warrants to purchase up to 13,330,000 shares at a combined price of $1.50 per share and accompanying warrants.
The Class A warrants have an initial exercise price of $1.50 per share, are immediately exercisable, and will expire after five years. Maxim Group acted as the exclusive placement agent. Azitra plans to use the net proceeds for working capital and general corporate purposes. The offering was made pursuant to an effective SEC registration statement, with a final prospectus available on the SEC's website.
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, has announced the pricing of a $10.0 million public offering. The offering includes 6,665,000 shares of common stock and Class A warrants to purchase up to 13,330,000 shares at a combined price of $1.50 per share and accompanying warrants. The warrants will have an initial exercise price of $1.50 per share, be immediately exercisable, and expire after five years. The offering is expected to close around July 25, 2024. Maxim Group is the exclusive placement agent. Azitra plans to use the net proceeds for working capital and general corporate purposes.
Azitra, Inc. (NYSE American: AZTR) has strengthened its global intellectual property portfolio with newly granted and allowed patents. The company received a U.S. patent for a filaggrin-secreting strain of Staphylococcus epidermidis to treat atopic dermatitis, along with additional patent allowances in the U.S., Canada, and China. These patents protect compositions and methods for treating inflammatory skin diseases using recombinant microorganisms.
The newly issued U.S. patent addresses atopic dermatitis, which affects approximately 16.5 million people in the United States. Azitra is developing live biotherapeutic product candidates for various skin diseases, focusing on precision dermatology. The company's approach involves delivering missing proteins, such as filaggrin, to the skin using engineered bacteria.
Azitra's patent portfolio now includes 4 granted U.S. patents, 14 granted international patents, and numerous pending applications, strengthening its position in the field of precision dermatology.
Azitra, a clinical-stage biopharmaceutical company, announced a reverse stock split of its common stock at a 1-for-30 ratio.
This change will be effective on July 1, 2024, when the stock will begin trading on a split-adjusted basis under the symbol AZTR. At a special stockholder meeting on June 27, 2024, the Board of Directors was granted the discretion to determine the split ratio, which was finalized at 1-for-30. The split will reduce the number of issued common shares from approximately 28.8 million to 960,155. No fractional shares will be issued; instead, stockholders will receive cash for any fractional shares based on the average closing prices of the common stock over the five days prior to the split.
The new CUSIP number for the split-adjusted shares will be 05479L 203. Stockholders with brokerage accounts will see automatic adjustments, and those holding certificated shares may choose to exchange certificates if desired.
Azitra, a clinical-stage biopharmaceutical company, will present at the 2024 BIO International Convention in San Diego. The presentation, scheduled for June 5 at 12:00 PM PDT, will be led by COO Travis Whitfill. Key updates will include progress on ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-induced dermal toxicity. The event runs from June 3-6, 2024.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, announced positive preclinical data for ATR-04, aimed at treating EGFR inhibitor-induced dermal toxicity. This condition affects about 150,000 patients in the US. The data, presented at the Society of Investigative Dermatology 2024 Annual Meeting, showed ATR-04 reducing methicillin-resistant S. aureus (MRSA) by 99% in ex vivo pig skin and reducing the pro-inflammatory cytokine IL-36γ by 75% in treated human skin models. Additionally, ATR-04 increased human beta defensin 18-fold compared to the vehicle in human skin models. These results support an upcoming IND application to the FDA for a Phase 1b trial in patients undergoing EGFR inhibitors with dermal toxicity.